| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000024187 |
| Receipt No. | R000027772 |
| Scientific Title | Effects of probucol and EPA on lipid component of HDL particles |
| Date of disclosure of the study information | 2016/11/01 |
| Last modified on | 2019/04/02 (Ver. 2) |
| Basic information | ||
| Public title | Effects of probucol and EPA on lipid component of HDL particles | |
| Acronym | Effects of probucol and EPA on lipid component of HDL particles | |
| Scientific Title | Effects of probucol and EPA on lipid component of HDL particles | |
| Scientific Title:Acronym | Effects of probucol and EPA on lipid component of HDL particles | |
| Region |
|
|
| Condition | |||
| Condition | Familial Hypercholesterolemia
Dyslipidemia |
||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | Analysis of changes of lipid species in HDL particles in patients with familial hypercholesterolemia and dyslipidemia after the treatment of probucol or EPA respectively. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Changes of lipid species in HDL particles after the treatment of probucol or EPA |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | (A)Treatment of probucol(500mg/day)in patients with familial hypercholesterolemia for 4 weeks
(B)Treatment of EPA(1800mg/day) in patients with dyslipidemia for 4 weeks |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (A)Probucol-treated group
Patients with familial hypercholesterolemia who does not take probucol 1)Hyper LDL-cholesterolemia 2)Taking lipid-lowering agents 3)LDL-c<200mg/dl 4)NYHA 1 or 2 5)>20 years old 6)AST<100IU/L, ALT<100IU/L, Cr<1.5mg/dL 7)Informed consent (B) EPA-treated group Patients with dyslipidemia who does not take EPA 1)>20 years old 2)Informed consent |
|||
| Key exclusion criteria | (A)Probucol-treated group
1)Taken probucol previously 2)Taking cyclosporin 3)Allergic to probucol 4)TG>400 mg/dL 5)HbA1c>8% 6)Frequent multifocal premature ventricular contraction 7)Atrial fibrillation 8)QTc>450msec(male),>470msec(female)on the ECG 9)Congestive heart failure or unstable angina 10)Participating in other trials 11)Pregnant (or might be pregnant) or lactating 12)The doctor decided to be inadequate for participating in this trial (B) EPA-treated group 1)Hemodialysis 2)Liver dysfunction 3)Active malignant diseases 4)Scheduled to undergo coronary angiography or CABG 5)Severe heart failure 6)ACS within 3 months 7)PCI or CABG within 3 months 8)HbA1c>8% 9)Secondary dyslipidemia or taking omega3 agents 10)Bleeding or bleeding tendency 11)Having past side effects for omega3 agents 12)Participating in other trials 13)Pregnant (or might be pregnant) or lactating 14)The doctor decided to be inadequate for participating in this trial |
|||
| Target sample size | 30 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | Osaka University Graduate School of Medicine | ||||||
| Division name | Cardiology | ||||||
| Zip code | |||||||
| Address | 2-2, Yamadaoka, Suita, Osaka | ||||||
| TEL | 06-6879-3631 | ||||||
| yasushisk@cardiology.med.osaka-u.ac.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | Osaka University Graduate School of Medicine | ||||||
| Division name | Cardiology | ||||||
| Zip code | |||||||
| Address | 2-2, Yamadaoka, Suita, Osaka | ||||||
| TEL | 06-6879-3633 | ||||||
| Homepage URL | |||||||
| ohama@cardiology.med.osaka-u.ac.jp | |||||||
| Sponsor | |
| Institute | Cardiology, Osaka University Graduate School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | self funding |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 大阪大学医学部付属病院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000027772 |